African trypanosomiasis is lethal if not treated and its incidence is increasing. Existing therapies are antique by contemporary standards and no vaccine is available. The DNA topoisomerases are enzymes essential for nucleic acid biosynthesis and cell survival and are proven targets for clinically vulnerable anti- infective and antitumor drugs. Previous work from this lab has established that topoisomerase inhibitors cause dramatic lesions in nuclear and mitochondrial (kinetoplast) DNA which are directly proportional to cell killing. This is an ongoing project to examine the DNA topoisomerases as targets for antitrypanosomal drug development, and as essential enzymes in DNA metabolism and cell survival.
The specific aims are two. First is to isolate and characterize native type I enzymes from trypanosomes, and to define the phenotypic consequence in trypanosomes of reducing or eliminating gene expression by knockout mutation or RNAi silencing.
The second aim i s to bring these basic molecular studies closer to the clinic by exploring the structure- activity relationship and selective toxicity of known topoisomerase IB poisons against trypanosomes in vitro, and by screening a defined chemical library to identify new topoisomerase poisons that are selectively toxic against trypanosomes. These studies take a multi-faceted, rational, and tangible approach to the development of much-needed new anti-trypanosomal chemotherapy.

Public Health Relevance

African sleeping sickness (trypanosomiasis) is an infection that is fatal if not treated and existing drugs are antiquated. This project is designed to discover new therapies for sleeping sickness based on interference with crucial steps in the DNA metabolism of trypanosomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56AI028855-16A1
Application #
7927670
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Rogers, Martin J
Project Start
1990-08-01
Project End
2011-08-31
Budget Start
2009-09-15
Budget End
2011-08-31
Support Year
16
Fiscal Year
2009
Total Cost
$410,000
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Nenortas, Nathaniel P; Cinelli, Maris A; Morrell, Andrew E et al. (2018) Activity of Aromathecins against African Trypanosomes. Antimicrob Agents Chemother 62:
Roy Chowdhury, Arnab; Bakshi, Rahul; Wang, Jianyang et al. (2010) The killing of African trypanosomes by ethidium bromide. PLoS Pathog 6:e1001226
Bakshi, Rahul P; Sang, Dongpei; Morrell, Andrew et al. (2009) Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother 53:123-8